Subscribe

New Bone-Targeting Compound Improves Survival in Metastatic Prostate Cancer

VBCC - October 2011, Volume 2, No 6 - ESMO 2011 Conference
Caroline Helwick

Jean-Charles Soria, MDStockholm, Sweden—An investigational alpha-pharmaceutical not only prevented skeletal-related events (SREs) in patients with prostate cancer with bone metastases in a phase 3 study presented at the 2011 European Multidisciplinary Cancer Congress, but it also improved overall survival.

“This is the first drug targeted to bone metastases in prostate cancer to improve survival,” said lead investigator Chris Parker, MD, Royal Marsden Hospital, London. “There are other bone drugs used in prostate cancer, but they help to minimize symptoms; they don’t improve survival. In my opinion, radium-223 is likely to become a new standard of treatment for advanced prostate cancer,” Dr Parker told journalists at a press briefing.

Jean-Charles Soria, MD, Institut Gustave Roussy, Villejuif, France, who cochaired the meeting’s scientific program, agreed. “This is really practice changing, and after regulatory approval, I think this is going to be a major player in advanced prostate cancer.”

A US coinvestigator of the trial, Oliver Sartor, MD, Tulane University, New Orleans, LA, said the radiopharmaceutical is far superior to prior compounds of the sort, and the study results were highly impressive.

Radium-223 chloride (Alpharadin) was recently granted a fast-track designation by the US Food and Drug Administration. The company plans to file a new drug application in mid-2012.

The Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial was a phase 3, randomized, doubleblind, placebo-controlled international study that compared radium-223 chloride plus current standard of care with placebo plus current standard of care in 922 men with symptomatic castration- resistant prostate cancer that had spread to the bone. Patients had multiple skeletal metastases on bone scan and were taking regular analgesics for bone pain.

At a planned interim analysis, the patients who received radium-223 had the following positive outcomes:

  • Median overall survival: 14 months compared with 11.2 months for the placebo group, a 30% reduction in mortality (P = .00185)
  • Time to first SREs: 13.6 months versus 8.4 months, a 64% improvement (P = .00046)
  • Total alkaline phosphatase (bone marker) normalization: 33% versus 1% (P <.001)
  • Time to prostate-specific antigen progression: 49% improvement (P = .00015).

Nonhematologic adverse events were not significantly worse with radium-223 versus placebo; the most common grade 3-4 adverse events were bone pain (18% vs 23%, respectively). Other serious toxicities were uncommon.

Based on the interim analysis, the data monitoring committee recommended the study be stopped and patients in the placebo arm be offered radium-223.

Related Items
Can Some Patients with Multiple Sclerosis Stop Treatment?
Caroline Helwick
Web Exclusives published on August 30, 2017 in Multiple Sclerosis
Oral Ozanimod: A Safer Sphingosine-1-Phosphate Receptor Modulator?
Caroline Helwick
Web Exclusives published on June 26, 2017 in Multiple Sclerosis
Vitamin D Supplementation Shows Benefits in Multiple Sclerosis, but Questions Remain
Caroline Helwick
Web Exclusives published on March 31, 2017 in Multiple Sclerosis
Ocrelizumab Receives Breakthrough Therapy for Progressive Multiple Sclerosis
Caroline Helwick
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Multiple Sclerosis
Ozanimod Achieves Very Low Relapse Rate in MS
Caroline Helwick
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Multiple Sclerosis
Stem-Cell Transplantation Shows Promise in Multiple Sclerosis, but Major Concerns Remain
Caroline Helwick
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Multiple Sclerosis
Treatment of Psoriatic Arthritis Explored by Cost-Effectiveness
Caroline Helwick
VBCR - June 2015, Volume 4, No 3 published on June 29, 2015 in Psoriatic Arthritis
Treatment Outcomes and Cost Assessed for Systemic Lupus Erythematosus
Caroline Helwick
VBCR - June 2015, Volume 4, No 3 published on June 29, 2015 in Lupus
Ankylosing Spondylitis Treatment Costs Assessed
Caroline Helwick
VBCR - June 2015, Volume 4, No 3 published on June 29, 2015 in Ankylosing Spondylitis
Patients with Myeloma Satisfied with Their Care but Feel Unprepared to Discuss Treatment Choices
Caroline Helwick
Value-Based Care in Myeloma published on February 26, 2015 in Multiple Myeloma
Last modified: August 12, 2016
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology